



ELEKTA CARRIES OUTS 3:1 SHARE SPLIT

PRESS RELEASE

Stockholm September 14, 2005

In accordance with a decision at the Annual General Meeting, effective Monday October 17, 2005, the Elekta share will be traded following a 3:1 split.

Taking into account the trend in market prices for the Elekta share, the Annual General Meeting held September 21, 2005 resolved to implement a share split in which each old A and each old B share held is replaced by three new shares of the same type.

The record date for the split was set at October 19, 2005, which means that the last day for trading in the share prior to the split is today, October 14, 2005.

In connection with the share split, the Stockholm Stock Exchange has decided to adjust the trading lot for the Elekta B share to 200.

After the split, Elekta will have 94,134,054 shares outstanding, including both A and B shares.

* * * * *

For further information, please contact:

International:

Peter Ejemyr
Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000
e-mail: peter.ejemyr@elekta.com

US:

Lars Jonsteg
VP Investor Relations North America, Elekta, USA
Tel: +46 708 78 37 35
e-mail: lars.jonsteg@elekta.com

About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain surgery and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, The Elekta Group is the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 3,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders. With approx. 1700 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTA.B.